478 related articles for article (PubMed ID: 26921823)
1. Effects of 16-month treatment with the cathepsin K inhibitor ONO-5334 on bone markers, mineral density, strength and histomorphometry in ovariectomized cynomolgus monkeys.
Yamada H; Ochi Y; Mori H; Nishikawa S; Hashimoto Y; Nakanishi Y; Tanaka M; Bruce M; Deacon S; Kawabata K
Bone; 2016 May; 86():43-52. PubMed ID: 26921823
[TBL] [Abstract][Full Text] [Related]
2. Effects of eight-month treatment with ONO-5334, a cathepsin K inhibitor, on bone metabolism, strength and microstructure in ovariectomized cynomolgus monkeys.
Ochi Y; Yamada H; Mori H; Nakanishi Y; Nishikawa S; Kayasuga R; Kawada N; Kunishige A; Hashimoto Y; Tanaka M; Sugitani M; Kawabata K
Bone; 2014 Aug; 65():1-8. PubMed ID: 24784023
[TBL] [Abstract][Full Text] [Related]
3. Cortical bone mineral density is increased by the cathepsin K inhibitor ONO-5334, which leads to a robust increase in bone strength: results from a 16-month study in ovariectomised cynomolgus monkeys.
Yamada H; Ochi Y; Mori H; Nishikawa S; Hashimoto Y; Tanaka M; Deacon S; Kawabata K
J Bone Miner Metab; 2019 Jul; 37(4):636-647. PubMed ID: 30357565
[TBL] [Abstract][Full Text] [Related]
4. Minodronic acid (ONO-5920/YM529) prevents decrease in bone mineral density and bone strength, and improves bone microarchitecture in ovariectomized cynomolgus monkeys.
Mori H; Tanaka M; Kayasuga R; Masuda T; Ochi Y; Yamada H; Kishikawa K; Ito M; Nakamura T
Bone; 2008 Nov; 43(5):840-8. PubMed ID: 18718565
[TBL] [Abstract][Full Text] [Related]
5. Long-term minodronic acid (ONO-5920/YM529) treatment suppresses increased bone turnover, plus prevents reduction in bone mass and bone strength in ovariectomized rats with established osteopenia.
Tanaka M; Mori H; Kayasuga R; Ochi Y; Kawada N; Yamada H; Kishikawa K
Bone; 2008 Nov; 43(5):894-900. PubMed ID: 18687415
[TBL] [Abstract][Full Text] [Related]
6. A comparative study of the bone metabolic response to dried plum supplementation and PTH treatment in adult, osteopenic ovariectomized rat.
Smith BJ; Bu SY; Wang Y; Rendina E; Lim YF; Marlow D; Clarke SL; Cullen DM; Lucas EA
Bone; 2014 Jan; 58():151-9. PubMed ID: 24125756
[TBL] [Abstract][Full Text] [Related]
7. Denosumab, a fully human RANKL antibody, reduced bone turnover markers and increased trabecular and cortical bone mass, density, and strength in ovariectomized cynomolgus monkeys.
Ominsky MS; Stouch B; Schroeder J; Pyrah I; Stolina M; Smith SY; Kostenuik PJ
Bone; 2011 Aug; 49(2):162-73. PubMed ID: 21497676
[TBL] [Abstract][Full Text] [Related]
8. Minodronic acid ameliorates vertebral bone strength by increasing bone mineral density in 9-month treatment of ovariectomized cynomolgus monkeys.
Tanaka M; Mori H; Kawabata K; Mashiba T
Bone; 2016 Jul; 88():157-164. PubMed ID: 27155564
[TBL] [Abstract][Full Text] [Related]
9. Odanacatib treatment increases hip bone mass and cortical thickness by preserving endocortical bone formation and stimulating periosteal bone formation in the ovariectomized adult rhesus monkey.
Cusick T; Chen CM; Pennypacker BL; Pickarski M; Kimmel DB; Scott BB; Duong LT
J Bone Miner Res; 2012 Mar; 27(3):524-37. PubMed ID: 22113921
[TBL] [Abstract][Full Text] [Related]
10. Treatment with a potent cathepsin K inhibitor preserves cortical and trabecular bone mass in ovariectomized monkeys.
Stroup GB; Kumar S; Jerome CP
Calcif Tissue Int; 2009 Oct; 85(4):344-55. PubMed ID: 19763376
[TBL] [Abstract][Full Text] [Related]
11. Odanacatib, effects of 16-month treatment and discontinuation of therapy on bone mass, turnover and strength in the ovariectomized rabbit model of osteopenia.
Duong LT; Crawford R; Scott K; Winkelmann CT; Wu G; Szczerba P; Gentile MA
Bone; 2016 Dec; 93():86-96. PubMed ID: 27639811
[TBL] [Abstract][Full Text] [Related]
12. ONO-5334, a cathepsin K inhibitor, improves bone strength by preferentially increasing cortical bone mass in ovariectomized rats.
Ochi Y; Yamada H; Mori H; Kawada N; Kayasuga R; Nakanishi Y; Tanaka M; Imagawa A; Ohmoto K; Kawabata K
J Bone Miner Metab; 2014 Nov; 32(6):645-52. PubMed ID: 24317478
[TBL] [Abstract][Full Text] [Related]
13. Balicatib, a cathepsin K inhibitor, stimulates periosteal bone formation in monkeys.
Jerome C; Missbach M; Gamse R
Osteoporos Int; 2011 Dec; 22(12):3001-11. PubMed ID: 21308366
[TBL] [Abstract][Full Text] [Related]
14. Decreased bone remodeling and porosity are associated with improved bone strength in ovariectomized cynomolgus monkeys treated with denosumab, a fully human RANKL antibody.
Kostenuik PJ; Smith SY; Jolette J; Schroeder J; Pyrah I; Ominsky MS
Bone; 2011 Aug; 49(2):151-61. PubMed ID: 21457806
[TBL] [Abstract][Full Text] [Related]
15. Balicatib, a cathepsin K inhibitor, stimulates periosteal bone formation in monkeys.
Jerome C; Missbach M; Gamse R
Osteoporos Int; 2012 Jan; 23(1):339-49. PubMed ID: 21380636
[TBL] [Abstract][Full Text] [Related]
16. Effects of long term treatment with high doses of odanacatib on bone mass, bone strength, and remodeling/modeling in newly ovariectomized monkeys.
Duong LT; Pickarski M; Cusick T; Chen CM; Zhuo Y; Scott K; Samadfam R; Smith SY; Pennypacker BL
Bone; 2016 Jul; 88():113-124. PubMed ID: 27126999
[TBL] [Abstract][Full Text] [Related]
17. Combination treatment with eldecalcitol (ED-71) and raloxifene improves bone mechanical strength by suppressing bone turnover and increasing bone mineral density in ovariectomized rats.
Takeda S; Sakai S; Shiraishi A; Koike N; Mihara M; Endo K
Bone; 2013 Mar; 53(1):167-73. PubMed ID: 23232307
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of cathepsin K increases modeling-based bone formation, and improves cortical dimension and strength in adult ovariectomized monkeys.
Pennypacker BL; Chen CM; Zheng H; Shih MS; Belfast M; Samadfam R; Duong LT
J Bone Miner Res; 2014 Aug; 29(8):1847-58. PubMed ID: 24591096
[TBL] [Abstract][Full Text] [Related]
19. Lycopene treatment against loss of bone mass, microarchitecture and strength in relation to regulatory mechanisms in a postmenopausal osteoporosis model.
Ardawi MM; Badawoud MH; Hassan SM; Rouzi AA; Ardawi JMS; AlNosani NM; Qari MH; Mousa SA
Bone; 2016 Feb; 83():127-140. PubMed ID: 26549245
[TBL] [Abstract][Full Text] [Related]
20. Abaloparatide, a novel PTH receptor agonist, increased bone mass and strength in ovariectomized cynomolgus monkeys by increasing bone formation without increasing bone resorption.
Doyle N; Varela A; Haile S; Guldberg R; Kostenuik PJ; Ominsky MS; Smith SY; Hattersley G
Osteoporos Int; 2018 Mar; 29(3):685-697. PubMed ID: 29260289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
